Novaferon - Genova Biotech Company
Alternative Names: Recombinant anti-tumour and anti-virus protein - Genova BiotechLatest Information Update: 03 Jan 2022
At a glance
- Originator Genova Biotech Company
- Developer Genova Biotech Company; M. D. Anderson Cancer Center; National Cancer Institute (USA); The Affiliated Hospital of the Chinese Academy of Military Medical Science
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II/III Colorectal cancer
- Phase II Hepatitis B
- Phase I/II Liver cancer
- No development reported Neuroendocrine tumours; Pancreatic cancer
Most Recent Events
- 28 Oct 2021 Phase-III clinical trials in COVID-2019 infections in Japan (Inhalation) (NCT05172037)
- 08 Sep 2021 No development reported - Phase-II for Neuroendocrine tumours (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (Parenteral)
- 08 Sep 2021 No development reported - Phase-II for Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in China (Parenteral)